Acromegalic patients lost to follow-up: A pilot study

Pituitary

Volumn 16, Issue 2, 2013, Pages 245-250

  Kasuki, Leandro ^a,b   Marques, Nelma Verônica ^a   Nuez, Maria José Braga La ^b   Leal, Vera Lucia Gomes ^c   Chinen, Renata N ^d   Gadelha, Mônica R ^a  

^a FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^b Bonsucesso Federal Hospital   (Brazil)

^c Instituto Estadual de Diabetes e Endocrinologia Luiz Capriglione   (Brazil)

^d Novartis Biociências SA   (Brazil)

Author keywords

Acromegaly; Chronic disease; Compliance; Follow up

Indexed keywords

CABERGOLINE; GLUCOSE; GLYCOSYLATED HEMOGLOBIN; GROWTH HORMONE; OCTREOTIDE; PEGVISOMANT; SOMATOMEDIN C;

ACROMEGALY; ADULT; ARTICLE; CLINICAL ARTICLE; DISEASE SEVERITY; FOLLOW UP; GLUCOSE BLOOD LEVEL; GROWTH HORMONE BLOOD LEVEL; HEMOGLOBIN BLOOD LEVEL; HUMAN; IMMUNOHISTOCHEMISTRY; MONOTHERAPY; ORAL GLUCOSE TOLERANCE TEST; PATIENT COMPLIANCE; PILOT STUDY; PREVALENCE; PRIORITY JOURNAL; SYMPTOM; TIME TO TREATMENT; TREATMENT DURATION;

ACROMEGALY; ADULT; AGED; CHRONIC DISEASE; FEMALE; HUMANS; LOST TO FOLLOW-UP; MALE; MIDDLE AGED;

EID: 84878762635     PISSN: 1386341X     EISSN: 15737403     Source Type: Journal    
DOI: 10.1007/s11102-012-0412-x     Document Type: Article

References (29)

1. Melmed S (2006) Medical progress: acromegaly. N Engl J Med 355(24):2558-2573
2. Holdaway IM, Bolland MJ, Gamble GD (2008) A meta-analysis of the effect of lowering serum levels of GH and IGF-I on mortality in acromegaly. Eur J Endocrinol 159(2):89-95
3. Melmed S, Colao A, Barkan A, Molitch M, Grossman AB, Kleinberg D, Clemmons D, Chanson P, Laws E, Schlechte J, Vance ML, Ho K, Giustina A (2009) Guidelines for acromegaly management: an update. J Clin Endocrinol Metab 94(5):1509-1517
4. Vieira Neto L, Abucham J, Araujo LA, Boguszewski CL, Bronstein MD, Czepielewski M, Jallad RS, Musolino NR, Naves LA, Ribeiro-Oliveira A Junior, Ribeiro-Oliveira A Jr, Vilar L, Faria Mdos S, Gadelha MR (2011) Recommendations of Neuroendocrinology Department from Brazilian Society of Endocrinology and Metabolism for diagnosis and treatment of acromegaly in Brazil. Arq Bras Endocrinol Metabol 55(2):91-105
5. Nomikos P, Buchfelder M, Fahlbusch R (2005) The outcome of surgery in 668 patients with acromegaly using current criteria of biochemical 'cure'. Eur J Endocrinol 152(3):379-387
6. Giustina A, Chanson P, Bronstein MD, Klibanski A, Lamberts S, Casanueva FF, Trainer P, Ghigo E, Ho K, Melmed S (2010) A consensus on criteria for cure of acromegaly. J Clin Endocrinol Metab 95(7):3141-3148
7. Carmichael JD, Bonert VS, Mirocha JM, Melmed S (2009) The utility of oral glucose tolerance testing for diagnosis and assessment of treatment outcomes in 166 patients with acromegaly. J Clin Endocrinol Metab 94(2):523-527
8. Ayuk J, Stewart PM (2009) Mortality following pituitary radiotherapy. Pituitary 12(1):35-39
9. Barkan A, Bronstein MD, Bruno OD, Cob A, Espinosa-de-los-Monteros AL, Gadelha MR, Garavito G, Guitelman M, Mangupli R, Mercado M, Portocarrero L, Sheppard M (2010) Management of acromegaly in Latin America: expert panel recommendations. Pituitary 13(2):168-175
10. Freda PU, Katznelson L, van der Lely AJ, Reyes CM, Zhao S, Rabinowitz D (2005) Long-acting somatostatin analog therapy of acromegaly: a meta-analysis. J Clin Endocrinol Metab 90(8):4465-4473
11. Murray RD, Melmed S (2008) A critical analysis of clinically available somatostatin analog formulations for therapy of acromegaly. J Clin Endocrinol Metab 93(8):2957-2968
12. Tutuncu, Y., Berker, D., Isik, S., Ozuguz, U., Akbaba, G., Kucukler, F.K., Aydin, Y., Guler, S.: Comparison of octreotide LAR and lanreotide autogel as post-operative medical treatment in acromegaly. Pituitary Aug 25 Epub ahead of print (2011)
13. Ramirez C, Vargas G, Gonzalez B, Grossman A, Rabago J, Sosa E, Espinosa-de-Los-Monteros AL, Mercado M (2012) Discontinuation of octreotide LAR after long term, successful treatment of patients with acromegaly: is it worth trying? Eur J Endocrinol 166(1):21-26
14. Ronchi CL, Rizzo E, Lania AG, Pivonello R, Grottoli S, Colao A, Ghigo E, Spada A, Arosio M, Beck-Peccoz P (2008) Preliminary data on biochemical remission of acromegaly after somatostatin analogs withdrawal. Eur J Endocrinol 158(1):19-25
15. Freda PU, Reyes CM, Nuruzzaman AT, Sundeen RE, Khandji AG, Post KD (2004) Cabergoline therapy of growth hormone & growth hormone/prolactin secreting pituitary tumors. Pituitary 7(1):21-30
16. Sandret L, Maison P, Chanson P (2011) Place of cabergoline in acromegaly: a meta-analysis. J Clin Endocrinol Metab 96(5):1327-1335
17. Vilar L, Azevedo MF, Naves LA, Casulari LA, Albuquerque JL, Montenegro RM, Montenegro RM Jr, Figueiredo P, Nascimento GC, Faria MS (2011) Role of the addition of cabergoline to the management of acromegalic patients resistant to longterm treatment with octreotide LAR. Pituitary 14(2):148-156
18. Verhelst JA, Abrams PJ, Abs R (2008) Remission of acromegaly following long-term therapy with cabergoline: report of two cases. Pituitary 11(1):103-107
19. Trainer PJ (2009) ACROSTUDY: the first 5 years. Eur J Endocrinol 161(Suppl 1):S19-S24
20. Trainer PJ, Drake WM, Katznelson L, Freda PU, Herman-Bonert V, van der Lely AJ, Dimaraki EV, Stewart PM, Friend KE, Vance ML, Besser GM, Scarlett JA, Thorner MO, Parkinson C, Klibanski A, Powell JS, Barkan AL, Sheppard MC, Malsonado M, Rose DR, Clemmons DR, Johannsson G, Bengtsson BA, Stavrou S, Kleinberg DL, Cook DM, Phillips LS, Bidlingmaier M, Strasburger CJ, Hackett S, Zib K, Bennett WF, Davis RJ (2000) Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant. N Engl J Med 342(16):1171-1177
21. Neggers SJ, van der Lely AJ (2011) Combination treatment with somatostatin analogues and pegvisomant in acromegaly. Growth Horm IGF Res 21(3):129-133
22. Muller, R., Kallikorm, R., Polluste, K., Lember, M.: Compliance with treatment of rheumatoid arthritis. Rheumatol Int Sep 29 Epub ahead of print (2011)
23. Gold DT (2006) Medication adherence: a challenge for patients with postmenopausal osteoporosis and other chronic illnesses. J Manag Care Pharm 12(6 Suppl A):S20-S25
24. Bex M, Abs R, T'Sjoen G, Mockel J, Velkeniers B, Muermans K, Maiter D (2007) AcroBel-the Belgian registry on acromegaly: a survey of the 'real-life' outcome in 418 acromegalic subjects. Eur J Endocrinol 157(4):399-409
25. Mestron A, Webb SM, Astorga R, Benito P, Catala M, Gaztambide S, Gomez JM, Halperin I, Lucas-Morante T, Moreno B, Obiols G, de Pablos P, Paramo C, Pico A, Torres E, Varela C, Vazquez JA, Zamora J, Albareda M, Gilabert M (2004) Epidemiology, clinical characteristics, outcome, morbidity and mortality in acromegaly based on the Spanish Acromegaly Registry (Registro Espanol de Acromegalia, REA). Eur J Endocrinol 151(4):439-446
26. Attanasio R, Montini M, Valota M, Cortesi L, Barbo R, Biroli F, Tonnarelli G, Albizzi M, Testa RM, Pagani G (2008) An audit of treatment outcome in acromegalic patients attending our center at Bergamo. Italy Pituitary 11(1):1-11
27. Neutel JM, Smith DH (2003) Improving patient compliance: a major goal in the management of hypertension. J Clin Hypertens (Greenwich) 5(2):127-132
28. Colao A, Ferone D, Marzullo P, Lombardi G (2004) Systemic complications of acromegaly: epidemiology, pathogenesis, and management. Endocr Rev 25(1):102-152
29. Kripalani S, Yao X, Haynes RB (2007) Interventions to enhance medication adherence in chronic medical conditions: a systematic review. Arch Intern Med 167(6):540-550